EA200970348A1 - Новые инъецируемые депо-композиции и способ получения таких композиций - Google Patents

Новые инъецируемые депо-композиции и способ получения таких композиций

Info

Publication number
EA200970348A1
EA200970348A1 EA200970348A EA200970348A EA200970348A1 EA 200970348 A1 EA200970348 A1 EA 200970348A1 EA 200970348 A EA200970348 A EA 200970348A EA 200970348 A EA200970348 A EA 200970348A EA 200970348 A1 EA200970348 A1 EA 200970348A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
new
composition
new injectable
tamsulosin
Prior art date
Application number
EA200970348A
Other languages
English (en)
Inventor
Раджеш Джаин
Коур Чанд Джиндал
Сампатх Кумар Девараджан
Original Assignee
Панацея Биотек Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Панацея Биотек Лтд. filed Critical Панацея Биотек Лтд.
Publication of EA200970348A1 publication Critical patent/EA200970348A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Заявлены новые инъецируемые композиции, содержащие активный агент, представляющий собой тамсулозин или летрозол, или их фармацевтически приемлемые соли, производные, изомеры, полиморфные модификации, сольваты, гидраты, аналоги, энантиомеры, таунтомерные формы или смеси вышеописанного с одним или более фармацевтически приемлемыми наполнителями, при этом композиции предпочтительно получают в виде биологически разлагаемых микрочастиц или наночастиц, которые в качестве варианта могут ресуспендироваться с водной, водно-спиртовой или жидкостно-маслянистой основой до их введения. Новые инъецируемые композиции настоящего изобретения предпочтительно образуют депо после введения in vivo и имеют форму местной гелеобразующей композиции или монолитной имплантируемой композиции, что обеспечивает пролонгированное высвобождение тамсулозина или летрозола в течение длительных периодов времени. Также описаны способ приготовления таких новых композиций и способ их применения.
EA200970348A 2006-10-05 2007-10-03 Новые инъецируемые депо-композиции и способ получения таких композиций EA200970348A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2195DE2006 2006-10-05
PCT/IN2007/000473 WO2008041246A2 (en) 2006-10-05 2007-10-03 Injectable depot composition and its' process of preparation

Publications (1)

Publication Number Publication Date
EA200970348A1 true EA200970348A1 (ru) 2009-10-30

Family

ID=39268891

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970348A EA200970348A1 (ru) 2006-10-05 2007-10-03 Новые инъецируемые депо-композиции и способ получения таких композиций

Country Status (17)

Country Link
US (2) US20100098735A1 (ru)
EP (2) EP2089000A2 (ru)
JP (2) JP2010505819A (ru)
KR (2) KR20090094811A (ru)
CN (2) CN101541316A (ru)
AR (1) AR063120A1 (ru)
AU (2) AU2007303794A1 (ru)
BR (2) BRPI0720346A2 (ru)
CA (2) CA2665101A1 (ru)
CL (1) CL2007002851A1 (ru)
EA (1) EA200970348A1 (ru)
IL (2) IL197946A0 (ru)
MA (2) MA30814B1 (ru)
MX (2) MX2009003735A (ru)
RU (1) RU2009116933A (ru)
TN (2) TN2009000125A1 (ru)
WO (2) WO2008041246A2 (ru)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
CA2510196C (en) 2002-12-20 2014-04-01 Generipharm, Inc. Intracutaneous injection
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
US20080319048A1 (en) * 2007-06-22 2008-12-25 Scidose Llc Solubilized formulation of docetaxel without tween 80
RU2485941C2 (ru) 2007-06-25 2013-06-27 Оцука Фармасьютикал Ко., Лтд. Микросферы, имеющие структуру ядро/оболочка
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2716576A1 (en) 2008-03-07 2009-09-11 Nageswara R. Palepu Fulvestrant formulations
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CN101569622B (zh) * 2008-04-30 2012-11-21 天津药物研究院 一种用于注射给药的药物制剂及其制备方法
EA014044B1 (ru) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты)
DK2341905T4 (da) * 2008-09-04 2023-12-11 Amylin Pharmaceuticals Llc Depotformuleringer med ikke-vandige bærere
WO2010066203A1 (en) * 2008-12-10 2010-06-17 Anhui Zhongren Technology Co., Ltd. Controlled releasing composition
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
US8673264B2 (en) 2009-03-02 2014-03-18 Assistance Publique-Hopitaux De Paris Injectable biomaterial
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
CN101669942A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 难溶性药物组合物
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
ES2654147T3 (es) 2009-11-16 2018-02-12 Ipsen Pharma S.A.S. Composiciones farmacéuticas de ligandos del receptor de melanocortina
RU2523566C2 (ru) * 2010-03-15 2014-07-20 Ипсен Фарма С.А.С. Фармацевтическая композиция лигандов рецепторов секретагогов гормона роста
EP2552416B1 (en) * 2010-03-29 2017-10-25 Evonik Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
RU2535089C2 (ru) * 2010-08-24 2014-12-10 Оцука Фармасьютикал Ко., Лтд. Суспензия и затвердевшая композиция, содержащие производное карбостирила и силиконовое масло и/или производное силиконового масла
EP2632463B1 (en) * 2010-10-28 2018-04-04 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for their transdermal delivery
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103442695B (zh) 2011-03-10 2016-05-04 Xeris药物公司 肠胃外注射用肽药物的稳定制剂
LT2685979T (lt) * 2011-03-18 2016-12-12 Alkermes Pharma Ireland Limited Injekcinės farmacinės kompozicijos, apimančios vandenyje netirpų antipsichotiką, sorbitano lauratą ir polisorbatą 20
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
PL2773331T3 (pl) 2011-10-31 2016-08-31 Xeris Pharmaceuticals Inc Preparaty do leczenia cukrzycy
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CN103483353B (zh) * 2012-06-13 2016-02-24 上海现代药物制剂工程研究中心有限公司 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
WO2014179615A2 (en) * 2013-05-01 2014-11-06 Dae Won Park Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
WO2015024133A1 (en) * 2013-08-22 2015-02-26 Polyvalor Limited Partnership Porous gels and methods for their preparation
JP2015093854A (ja) * 2013-11-12 2015-05-18 株式会社クレハ 水性組成物および加水分解抑制方法
CH708890B1 (de) * 2013-11-22 2018-03-15 Sandel Thomas Ball, vorzugsweise Golfball, sowie ein mit dem Ball kommunizierbares elektronisches Gerät.
US20150174254A1 (en) 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3217959A1 (en) * 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions for hepatitis c
EP3028721A1 (en) * 2014-12-05 2016-06-08 Exchange Imaging Technologies GmbH Nanoparticle formulation having reverse-thermal gelation properties for injection
KR101692314B1 (ko) * 2015-03-27 2017-01-03 주식회사 주빅 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
EP3458070A4 (en) * 2016-05-16 2020-01-08 Amag Pharmaceuticals, Inc. PROLONGED RELEASE POLYMER COMPOSITIONS BASED ON HYDROXYPROGESTERONE CAPROATE AND METHODS OF USE THEREOF
TWI814219B (zh) 2016-05-16 2023-09-01 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
TW201834640A (zh) * 2017-01-23 2018-10-01 展旺生命科技股份有限公司 活性成分微粒的製備方法
CN106822042A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 一种利培酮缓释组合物及其制备方法
CN106822043A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 利培酮缓释组合物及其制备方法
CN116270486A (zh) * 2017-01-24 2023-06-23 广州帝奇医药技术有限公司 水难溶或微溶性药物缓释组合物及其制备方法
CN106727422B (zh) * 2017-03-09 2018-10-02 王秋玉 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
BR112020004978A2 (pt) * 2017-09-15 2020-09-15 Oxular Limited composição farmacológica liofilizada estéril, formulação farmacêutica, forma farmacêutica unitária, kit, método para o tratamento de uma doença ou afecção, método para o tratamento de uma doença ou afecção ocular e composição farmacológica, composição farmacológica para uso
CN112074269A (zh) * 2018-03-23 2020-12-11 美卓实验室 用于男性避孕的非激素组合物和方法
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
WO2020256340A2 (ko) 2019-06-21 2020-12-24 고려대학교산학협력단 체내 부피 유지 제제, 이를 포함하는 주사제 및 이의 제조방법
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
CN111956599B (zh) * 2020-09-29 2023-02-17 江苏集萃新型药物制剂技术研究所有限公司 皮下植入药剂及其组合物和制备方法
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
KR102652905B1 (ko) * 2021-08-09 2024-04-01 주식회사 메디폴리머 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
CN116850146B (zh) * 2023-05-22 2024-05-14 济南大学 伏硫西汀自由碱或其药用盐长效缓释制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
EP0669128B1 (en) * 1992-11-17 2000-01-05 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
WO2002058672A2 (en) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
EP1450766B1 (fr) * 2001-10-10 2015-04-22 Pierre Fabre Medicament Microspheres biodegradables a liberation prolongee et leur procede de preparation
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms

Also Published As

Publication number Publication date
CA2665105A1 (en) 2008-04-10
WO2008041245A2 (en) 2008-04-10
EP2086505A2 (en) 2009-08-12
BRPI0718288A2 (pt) 2013-11-19
JP2010505819A (ja) 2010-02-25
WO2008041246A2 (en) 2008-04-10
CN101541313A (zh) 2009-09-23
BRPI0720346A2 (pt) 2014-06-24
IL197946A0 (en) 2009-12-24
JP2010505821A (ja) 2010-02-25
AU2007303793A1 (en) 2008-04-10
CA2665101A1 (en) 2008-04-10
MX2009003737A (es) 2009-06-16
TN2009000124A1 (en) 2010-10-18
IL197947A0 (en) 2009-12-24
KR20090087441A (ko) 2009-08-17
US20100098735A1 (en) 2010-04-22
EP2089000A2 (en) 2009-08-19
WO2008041245A3 (en) 2008-05-22
CL2007002851A1 (es) 2008-01-18
MA30817B1 (fr) 2009-10-01
MX2009003735A (es) 2009-04-22
KR20090094811A (ko) 2009-09-08
WO2008041246A3 (en) 2008-05-29
AU2007303794A1 (en) 2008-04-10
AR063120A1 (es) 2008-12-30
RU2009116933A (ru) 2010-11-10
US20100015195A1 (en) 2010-01-21
TN2009000125A1 (en) 2010-10-18
CN101541316A (zh) 2009-09-23
MA30814B1 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
EA200970348A1 (ru) Новые инъецируемые депо-композиции и способ получения таких композиций
MA37661B1 (fr) Formulation pour implant contenant de la palipéridone
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
CO2022000254A2 (es) Composición farmacéutica para suministro nasal
MA37664B1 (fr) Formulation pour implant contenant de la rispéridone et/ou de la palipéridone
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200870368A1 (ru) Антибиотические композиции с модифицированным высвобождением и способ их получения
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200800162A1 (ru) Новые фармацевтические композиции с замедленным высвобождением и способы их получения
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
JP2010530376A5 (ru)
WO2005065646A3 (en) Novel drug compositions and dosage forms
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
PE20050772A1 (es) Piperidinilcarbonil-pirrolidinas como agonistas de melanocortina
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201391018A1 (ru) Препараты иммуносупрессантов
TW201129396A (en) Topical formulation
BRPI0511979A (pt) derivados de triazóis substituìdos como antagonistas de oxitocina, composição farmacêutica compreendendo os referidos derivados, bem como uso dos mesmos
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
AR038947A1 (es) Suspension oral de sabor agradable y metodo
JP2005511491A5 (ru)